Brief: Ocumension Therapeutics Says CDE Approval Received For A Phase Iii Clinical Trial Of Ot-101
13/07/2021 11:41
July 13 (Reuters) - Ocumension Therapeutics 1477.HK :
* CDE APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF
OT-101
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application